Status Change

Baili's BL-B01D1 opens enrollment in first-line esophageal cancer trial

The Phase 2/3 PANKU-Esophagus02 trial began recruiting patients for a randomized test of the ADC against platinum chemotherapy, both paired with tislelizumab.

By AppliedXLJuly 16, 2026Trial NCT07554456

Executive Summary

Sichuan Baili Pharmaceutical's Phase 2/3 trial of BL-B01D1 in first-line esophageal squamous cell carcinoma moved into active recruitment, on schedule and with its enrollment target unchanged.
The trial randomizes patients to BL-B01D1 combined with a checkpoint inhibitor against the chemotherapy-plus-checkpoint-inhibitor regimen that anchors current first-line treatment, with survival as the deciding measure.
This is Baili's second registrational study of the same antibody-drug conjugate in the same cancer, run alongside an earlier trial that has already stopped recruiting and is tracking toward its own primary completion.
PD-1-targeted therapy in this cancer is an active field with dozens of programs, but the historical failure rate among completed trials at this stage has been low, and no trial in the class has yet reported a resolved outcome that changes that read.

The status change

NCT07554456, known as PANKU-Esophagus02, switched from Not yet recruiting to Recruiting on July 16, 2026, according to its registry record. The Phase 2/3 trial plans to enroll 90 adults with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma who have not received prior systemic treatment. Patients are randomized to BL-B01D1 combined with tislelizumab, with or without 5-fluorouracil, against platinum-based chemotherapy plus tislelizumab. The trial started June 9, 2026, and lists a primary completion date of December 1, 2028. NCT07554456

Probability of Success

Endpoint Met34%

Completes79%

Clinical Significance19%

Regulatory75%

The endpoint

Overall survival is the sole primary endpoint, measured from randomization to death over an assessment window of roughly 24 months. Secondary measures include progression-free survival, objective response rate, disease control rate, duration of response, time to response, and treatment-emergent adverse events. Overall survival is the endpoint regulators weigh most heavily in first-line tumor trials, and it is a harder bar to clear than a response-rate endpoint because it requires the drug to extend life, not just shrink tumors. NCT07554456

The second trial

Baili already runs one other registrational trial of BL-B01D1 in the same cancer, NCT06304974 (PANKU-Esophagus01), which compares the drug against chemotherapy of physician's choice in the recurrent or metastatic setting and has stopped recruiting with a primary completion date of May 1, 2026. PANKU-Esophagus02 moves the same drug into the first-line, chemo-immunotherapy-combination setting, testing whether the antibody-drug conjugate adds benefit when layered onto an established checkpoint-inhibitor backbone rather than replacing chemotherapy outright. NCT07554456

The competitive field

PD-1-targeted programs are active in esophageal squamous cell carcinoma, with 23 ongoing trials pairing the target with this indication and 71 trials total across 48 sponsors. Among completed Phase 2 trials in this target-indication pair, one of 14 terminated, a failure rate near 7%. The closest direct comparator is Merck's sacituzumab tirumotecan, another PD-1-linked antibody-drug conjugate now in Phase 3 testing, though in triple-negative breast cancer rather than this indication. Within esophageal squamous cell carcinoma specifically, BeOne Medicines' tislelizumab, the same checkpoint inhibitor used as the comparator backbone here, is also being tested in a separate Phase 2 gastric adenocarcinoma trial, underscoring how tightly the PD-1 checkpoint-inhibitor combination has become the default backbone against which new agents are layered. Given that established backbone, a survival advantage over platinum chemotherapy plus tislelizumab, sustained through the trial's roughly two-year assessment window, is the result that would separate BL-B01D1 from the standard rather than merely replicate it.

Operational read

The enrollment target of 90 patients is unchanged from the trial's original registration, within the routine range the operational model uses to flag material shifts. The trial's registry history shows one status update since its initial posting in April 2026, consistent with a stable early-stage record. NCT07554456

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.